Dihydroergotamine

Drug class: Antineoplastic Agents

Usage of Dihydroergotamine

Vascular Headaches

Acute treatment of migraine attacks (with or without aura) or cluster headaches.

One of several preferred initial therapies in moderate to severe migraines or mild to moderate migraines that respond poorly to NSAIAs.

IV treatment of intractable migraines† [off-label] (e.g., status migrainosus† [off-label]); usually used in combination with IV antiemetic.

Not recommended for management of hemiplegic or basilar migraine or for prophylaxis or chronic daily management of migraine.

Other Uses

Used in combination with low-dose heparin therapy for prevention of postoperative DVT and pulmonary embolism; generally has been replaced by other more effective therapies (e.g., low molecular weight heparin alone, warfarin).

Relate drugs

How to use Dihydroergotamine

General

Vascular Headaches
  • Administer as soon as possible after onset of first symptoms of vascular headache.
  • After administering the initial dose, patient should lie down and relax in a quiet, darkened room.

    • Administration

    Administer by IM, IV, or sub-Q injection or by nasal inhalation using a spray pump.

    Administer by nasal inhalation or by IM, sub-Q, or direct IV injection for the acute treatment of migraine; if self-administration by parenteral route is desired, sub-Q injection generally is preferred because of ease of administration.

    Administer by IM, sub-Q, or direct IV injection for the acute treatment of cluster headaches; sub-Q injection generally is preferred for self-administration because of ease of administration.

    Administer by direct IV injection or continuous IV infusion† [off-label] for the acute treatment of intractable migraines in an inpatient setting.

    Dihydroergotamine preparations are not recommended for prolonged daily use.

    Intranasal Administration

    Nasal solution intended for topical intranasal use only, and must not be injected.

    Prior to initial use, assemble and fully prime the spray pump (i.e., spray 4 times). Consult the manufacturer’s patient instructions for information on assembly, priming, and use of the nasal spray pump.

    Spray once in each nostril; wait 15 minutes and spray once again in each nostril. Do not tilt head back or inhale through nose while administering the drug.

    Discard nasal spray applicator (with any remaining drug in opened ampul) 8 hours after assembly.

    IV Administration

    For solution and drug compatibility information, see Compatibility under Stability.

    To minimize adverse local effects, some clinicians suggest flushing the IV line or port with 10–20 mL of sodium chloride 0.45 or 0.9% prior to administering the drug. Do not mix with buffers (e.g., sodium bicarbonate, sodium acetate) to minimize local adverse effects (see Compatibility under Stability).

    Dilution

    For continuous IV infusion† [off-label], add 3 mg of dihydroergotamine mesylate in 1 L of sodium chloride 0.9%, resulting in a final concentration of 3 mcg/mL.

    Rate of Administration

    May administer undiluted by direct IV injection over 1–2 minutes.

    Has been administered by continuous IV infusion† [off-label] as a 3-mcg/mL solution at a rate of 126 mcg (42 mL) per hour.

    Sub-Q Administration

    Administer sub-Q into the middle of thigh after aspiration (to guard against accidental intravascular injection).

    To minimize adverse local effects, some clinicians suggest diluting usual sub-Q dose (1 mg) with 1 mL of sodium chloride 0.9%. Do not mix with buffers (e.g., sodium bicarbonate, sodium acetate) to minimize local adverse effects (see Compatibility under Stability).

    Dosage

    Available as dihydroergotamine mesylate; dosage expressed in terms of the salt.

    Adults

    Vascular Headaches Migraine Intranasal

    0.5 mg (1 spray) in each nostril (1 mg total) initially; repeat 15 minutes later for a total dose of 2 mg. Higher dosages provide no additional benefit.

    IV

    1 mg by direct IV injection initially, followed by 1 mg at 1-hour intervals until the attack has abated or a total of 2 mg has been given in a 24-hour period.

    Alternatively, 3 mg has been administered by continuous IV infusion† over 24 hours for the treatment of intractable migraines.

    IM

    1 mg initially, followed by 1 mg at 1-hour intervals until the attack has abated or a total of 3 mg has been given in a 24-hour period.

    Sub-Q

    1 mg initially, followed by 1 mg at 1-hour intervals until the attack has abated or a total of 3 mg has been given in a 24-hour period.

    Cluster Headaches IV

    1 mg initially, followed by 1 mg at 1-hour intervals until the attack has abated or a total of 2 mg has been given in a 24-hour period.

    IM

    1 mg initially, followed by 1 mg at 1-hour intervals until the attack has abated or a total of 3 mg has been given in a 24-hour period.

    Sub-Q

    1 mg initially, followed by 1 mg at 1-hour intervals until the attack has abated or a total of 3 mg has been given in a 24-hour period.

    Prescribing Limits

    Adults

    Vascular Headaches Intranasal

    Safety of >3 mg in any 24-hour period and >4 mg in any 7-day period has not been established.

    IV

    Maximum 2 mg in any 24-hour period.

    Maximum total weekly dosage: 6 mg.

    IM

    Maximum 3 mg in any 24-hour period.

    Maximum total weekly dosage: 6 mg.

    Sub-Q

    Maximum 3 mg in any 24-hour period.

    Maximum total weekly dosage: 6 mg.

    Warnings

    Contraindications

  • Known or suspected pregnancy and in nursing women.
  • Concomitant therapy with peripheral or central vasoconstrictors or potent CYP3A4 inhibitors; recent (i.e., 24 hours) therapy with a 5-HT1 receptor agonist (e.g., sumatriptan) or an ergot alkaloid (e.g., ergotamine, methysergide). (See Interactions.)
  • Known or suspected ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, documented silent ischemia) or coronary artery vasospasm (e.g., Prinzmetal variant angina).
  • Known peripheral arterial disease, uncontrolled hypertension, or following vascular surgery.
  • Severe hepatic or renal impairment.
  • Sepsis.
  • Basilar or hemiplegic migraine.
  • Known hypersensitivity to ergot alkaloids.

    • Warnings/Precautions

    Warnings

    Use only in patients in whom a clear diagnosis of migraine has been established.

    Fetal/Neonatal Morbidity and Mortality

    May cause fetal harm; developmental toxicity observed in animals. Possesses oxytocic properties.

    If used during pregnancy, or if pregnancy occurs during therapy, apprise the patient of the potential hazard to the fetus.

    Fibrosis

    Retroperitoneal and pleuropulmonary fibrosis reported following long-term daily use. Possible fibrotic thickening of cardiac valves with continuous, long-term administration.

    Do not administer on a chronic daily basis.

    Cardiac Effects

    Possible myocardial ischemia and/or infarction, coronary vasospasm, life-threatening cardiac rhythm disturbance, and death. (See Contraindications.)

    Use not recommended in patients in whom unrecognized CAD is likely (e.g., postmenopausal women, men >40 years of age, patients with risk factors such as hypertension, hypercholesterolemia, obesity, diabetes mellitus, smoking, or family history of CAD) unless there is satisfactory evidence from a prior cardiovascular evaluation that the patient does not have CAD, ischemic heart disease, or other underlying cardiovascular disease.

    Administer initial dose to patients with risk factors for CAD who have completed satisfactory cardiovascular evaluation under medical supervision (e.g., in clinician’s office, possibly followed by ECG) unless patient previously received the drug.

    Periodic cardiovascular evaluation recommended in patients with risk factors for CAD if receiving intermittent long-term therapy.

    Patients with symptoms suggestive of angina after receiving dihydroergotamine should be evaluated for presence of CAD or predisposition to Prinzmetal variant angina before receiving additional doses.

    Cerebrovascular Events

    Possible cerebral or subarachnoid hemorrhage, stroke, and other cerebrovascular events, sometimes fatal.

    Risk of certain cerebrovascular events (e.g., stroke, hemorrhage, transient ischemic attack) may be increased in patients with migraine.

    Other Cardiovascular or Vasospastic Effects

    Peripheral vascular ischemia and colonic ischemia reported. Further evaluation recommended if signs or symptoms suggestive of decreased arterial flow (e.g., manifestations of ischemic bowel syndrome or Raynaud’s phenomenon) occur following administration.

    Substantial increases in BP reported rarely in patients with or without history of hypertension. (See Contraindications.)

    Increases in mean pulmonary artery pressure observed following administration of another 5-HT1 receptor agonist to patients with suspected CAD who were undergoing cardiac catheterization.

    Ergotism

    Potential for ergotism, manifested by intense arterial vasoconstriction, producing signs and symptoms of peripheral vascular ischemia; if left untreated, can progress to gangrene. Do not exceed recommended dosages.

    If signs and symptoms of impaired circulation occur, immediately discontinue therapy.

    Local Effects of Intranasal Administration

    Nasal or throat irritation reported frequently following intranasal administration (see Common Adverse Effects under Cautions). Effects of long-term, repeated administration on nasal and respiratory mucosa have not been systematically evaluated to date; however, nasal and throat examinations performed in a limited number of patients revealed no evidence of mucosal injury following repeated administration over periods up to 36 months.

    Specific Populations

    Pregnancy

    Category X. (See Fetal/Neonatal Morbidity and Mortality and also see Contraindications, under Cautions.)

    Lactation

    Not known whether dihydroergotamine is distributed into milk; however, ergotamine is distributed into milk and may cause vomiting, diarrhea, weak pulse, and unstable BP in nursing infants. Dihydroergotamine is contraindicated in nursing women.

    Inhibits prolactin.

    Pediatric Use

    Safety and efficacy not established in children.

    Geriatric Use

    Insufficient experience with intranasal dihydroergotamine in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.

    Hepatic Impairment

    Contraindicated in patients with severe hepatic impairment.

    Renal Impairment

    Contraindicated in patients with severe renal impairment.

    Common Adverse Effects

    With parenteral dihydroergotamine, vasospasm, paresthesia, hypertension, dizziness, anxiety, dyspnea, headache, flushing, diarrhea, rash, increased sweating.

    With intranasal dihydroergotamine, mild-to-moderate nasal or throat irritation (e.g., congestion, burning sensation, dryness, paresthesia, discharge, epistaxis, pain, soreness), taste disturbances, rhinitis, application site reactions, dizziness, nausea, vomiting.

    What other drugs will affect Dihydroergotamine

    Extensively metabolized, principally by CYP3A4. Inhibits CYP3A.

    Drugs Affecting Hepatic Microsomal Enzymes

    Potent CYP3A4 inhibitors: Potential pharmacokinetic interaction (increased serum dihydroergotamine concentrations); potentially fatal cerebral ischemia and/or ischemia of the extremities possible. Concomitant use with potent CYP3A4 inhibitors contraindicated.

    Less-potent CYP3A4 inhibitors: Similar effects not reported to date; however, consider possibility of serious toxicity during concomitant use.

    Specific Drugs and Foods

    Drug or Food

    Interaction

    Comment

    Antidepressants, SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline)

    Weakness, hyperreflexia, and/or incoordination reported rarely with other 5-HT1 receptor agonists

    Potential decrease in dihydroergotamine metabolism

    Use with caution

    Antifungals, azole (e.g., fluconazole, itraconazole, ketoconazole)

    Potent CYP3A4 inhibitors (e.g., itraconazole, ketoconazole): Inhibition of dihydroergotamine metabolism and increased risk of potentially fatal cerebral ischemia and/or ischemia of the extremities

    Less potent CYP3A4 inhibitors (e.g., fluconazole): Potential decrease in dihydroergotamine metabolism

    Concomitant use of potent CYP3A4 inhibitors contraindicated

    Use less potent CYP3A4 inhibitors with caution

    Clotrimazole

    Potential decrease in dihydroergotamine metabolism

    Use with caution

    Ergot alkaloids (e.g., ergotamine, methysergide)

    Potential for excessive vasoconstriction

    Use within 24 hours contraindicated

    Grapefruit juice

    Potential decrease in dihydroergotamine metabolism

    Use with caution

    HIV protease inhibitors (e.g., ritonavir, nelfinavir, indinavir, saquinavir)

    Potent CYP3A4 inhibitors (e.g., ritonavir, nelfinavir, indinavir): Inhibition of dihydroergotamine metabolism and increased risk of potentially fatal cerebral ischemia and/or ischemia of the extremities

    Less potent CYP3A4 inhibitors (e.g., saquinavir): Potential decrease in dihydroergotamine metabolism

    Concomitant use of potent CYP3a4 inhibitors contraindicated

    Use less potent CYP3A4 inhibitors with caution

    Macrolide antibiotics (e.g., erythromycin, clarithromycin, troleandomycin)

    Inhibition of dihydroergotamine metabolism; increased risk of potentially fatal cerebral ischemia and/or ischemia of the extremities

    Concomitant use contraindicated

    Nefazodone

    Potential decrease in dihydroergotamine metabolism

    Use with caution

    Nicotine

    Possible vasoconstriction and increased ischemic response

    Use with caution

    Propranolol

    Potentiation of dihydroergotamine's vasoconstrictive action

    Use with caution

    Serotonin (5-HT1) receptor agonists (e.g., sumatriptan)

    Additive vasoconstrictor effects

    Use within 24 hours contraindicated

    Vasoconstrictors, peripheral or central

    Additive increases in BP

    Concomitant use contraindicated

    Zileuton

    Potential decrease in dihydroergotamine metabolism

    Use with caution

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant